investigation and Comparison of the effect of Daflon and pentoxifylline in the treatment of patients with chronic venous insufficiency

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20221213056808N1

Enrollment

100

Registered

2023-04-17

Start date

2023-02-20

Completion date

Unknown

Last updated

2023-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with chronic venous insufficiency. Venous insufficiency (chronic) (peripheral)

Interventions

Intervention 1: The first intervention group: patients who entered the study according to the inclusion criteria and were treated with pentoxifylline tablets (from Farabi company) at a dose of 400 mg

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Chronic venous insufficiency disease with class C2 and more according to CEAP criteria Consent to take medicine Ability to communicate

Exclusion criteria

Exclusion criteria: Patients who are candidates for surgery Patients who do not take medicine

Design outcomes

Primary

Measure	Time frame
CEAP( classification stands for Clinical (C), Etiological (E), Anatomical (A), and Pathophysiological (P)) Score. Timepoint: At the beginning of the study and 6 months after taking the drug. Method of measurement: C0: no obvious features of the disease: C1: spider veins C2: obvious varicose veins: C3: edema: C4: eczema and skin discoloration: C5: healing wounds C6: active wounds with exudation.;Venous Clinical Severity Score(vcss score). Timepoint: At the beginning of the study and 6 months after taking the drug. Method of measurement: Pigmentation: 0-2 Vascularity: 0-5 Pliability: 0-5 Height: 0-3.	—

Measure

Time frame

CEAP( classification stands for Clinical (C), Etiological (E), Anatomical (A), and Pathophysiological (P)) Score. Timepoint: At the beginning of the study and 6 months after taking the drug. Method of measurement: C0: no obvious features of the disease: C1: spider veins C2: obvious varicose veins: C3: edema: C4: eczema and skin discoloration: C5: healing wounds C6: active wounds with exudation.;Venous Clinical Severity Score(vcss score). Timepoint: At the beginning of the study and 6 months after taking the drug. Method of measurement: Pigmentation: 0-2 Vascularity: 0-5 Pliability: 0-5 Height: 0-3.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactIman Heidari

Gorgan University of Medical Sciences

Imanheidari72@gmail.com+98 17 3252 7741

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026